Clinical trials: Optic Atrophy
Parkinson's Disease, Progressive Supranuclear Palsy(PSP)
Study on Artificial Intelligence-Based Facial and Speech-Related Patterns in Parkinson's Disease and Their Digital Biomarkers
This research employs AI to analyze facial expressions and speech patterns, aiming to develop new digital tools for diagnosing and differentiating Parkinson's disease and similar disorders.
- Conditions
- Parkinson's Disease, Progressive Supranuclear Palsy(PSP), Multiple System Atrophy, Healthy Control
- Trial name
- NCT07392411
- Testing
- video recording
- Where
- China
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Beijing Tiantan Hospital
Dry Eye Syndromes, Meibomian Gland Dysfunction (Disorder)
Blink Reminders and Meibomian Gland Loss in Digital Screen Users
This randomized clinical trial aims to evaluate if a blink reminder program ('BlinkEasy') reduces the progression of Meibomian gland loss in intensive digital screen users over three months , using infrared meibography as the…
- Trial name
- NCT07430137
- Testing
- Digital Blink Reminder Software (BlinkEasy), Visual Hygiene Education (20-20-20 Rule).
- Volunteers
- 28 people
- Sponsor
- Asociación para Evitar la Ceguera en México
Retinal Dystrophies, Geographic Atrophy
Real-time Acoustic Biofeedback for Enhancing Fixation Stability: A Proof-of-concept Study to Improve Ophthalmic Imaging Diagnostic Quality
The goal of this Proof of Concept Feasibility Study is to improve the fixation stability in patients with fixation loss due to blindness or central vision loss using a patented acoustic real-time feedback device.
- Conditions
- Retinal Dystrophies, Geographic Atrophy, Blindness
- Trial name
- NCT07529041
- Testing
- A device providing acoustic real-time biofeedback
- Where
- Germany
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University Medical Center Goettingen
Parkinson's Disease, Alzheimer's Disease
Biomarkers in Neural Disorders
This study seeks to establish the sensitivity and specificity of what appears to be a unique brainstem biomarker of Parkinson's Disease (PD) - an electrically induced olygosynaptic nasotrigeminal reflex response - in…
- Conditions
- Parkinson's Disease, Alzheimer's Disease, Progressive Supranuclear Palsy, Essential Tremor
- Trial name
- NCT02761707
- Testing
- Electrical Brainstem Responses, Olfactory Tests, Visual Deprivation
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Neurologic Disorders, Nervous System Diseases
Neurologic Stem Cell Treatment Study
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will…
- Conditions
- Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders
- Trial name
- NEST (NCT02795052)
- Testing
- Intravenous and Intranasal BMSC
- Where
- 3 sites in United States, United Arab Emirates
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Geographic Atrophy
CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA)
The purpose of this study is to evaluate the safety and efficacy of 12 (every 28 days) intravitreal (IVT) injections of CLG561 as a monotherapy and in combination with LFG316 as compared to sham in subjects with geographic…
- Trial name
- NCT02515942
- Testing
- CLG561, LFG316
- Volunteers
- 114 people
- Sponsor
- Alcon Research
Age-Related Macular Degeneration
A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients
The purpose of this study was to compare the development of new geographic atrophy in patients with wet Age-related Macular Degeneration (AMD) when treated with either ranibizumab or aflibercept over 24 months.
- Trial name
- RIVAL (NCT02130024)
- Testing
- Ranibizumab 0.5 mg, Aflibercept 2.0 mg
- Where
- 22 sites in Australia
- Volunteers
- 281 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Macular Degeneration
Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration
Background: Age-related macular degeneration (AMD) is the main reason older people lose their vision. It affects the macula, the center of the retina needed for sharp, clear vision.
- Trial name
- NCT02564978
- Testing
- Minocycline
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Eye Institute (NEI)
Pathologic Myopia
LED Red Light in Modulating Choroidal Microcirculation to Retard Retinal Atrophy in Pathological Myopia
The goal of this clinical trial is to learn if LED repeated low-level red light (RLRL) therapy works to treat pathologic myopia in adults. It will also learn about the safety of LED-RLRL.
- Trial name
- NCT07312214
- Testing
- LED red light
- Where
- China
- Volunteers
- 158 people
- Sponsor
- Shanghai Eye Disease Prevention and Treatment Center
Dry Age-related Macular Degeneration, Geographic Atrophy
Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA)
Patients with advanced dry AMD with GA meeting inclusion criteria will be randomized in one eye in a 1:1:1 ratio comparing intravitreal high or low dose AAVCAGsCD59 with a sham injection.
- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy, Gene Therapy, Intravitreal Injection
- Trial name
- NCT04358471
- Testing
- Intravitreal AAVCAGsCD59
- Sponsor
- Hemera Biosciences
Parkinson Disease Dementia, Parkinson Disease
Community Outreach for Palliative Engagement -- Parkinson Disease
The purpose of this study is to learn more about the effectiveness of palliative care training for community physicians and telemedicine support services for patients and carepartners with Parkinson's disease and Lewy Body…
- Conditions
- Parkinson Disease Dementia, Parkinson Disease, Parkinson's Disease and Parkinsonism, Lewy Body Parkinsonism
- Trial name
- COPE-PD (NCT05222386)
- Testing
- Parkinson Disease Standard Care, Online Community-Supported Palliative Care
- Where
- United States
- Volunteers
- 632 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Geographic Atrophy
A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study evaluating the efficacy and safety of lampalizumab administered by intravitreal injections in participants with geographic atrophy…
- Trial name
- SPECTRI (NCT02247531)
- Testing
- Lampalizumab
- Where
- 153 sites in United States, Argentina and 20 more
- Volunteers
- 975 people
- Sponsor
- Hoffmann-La Roche
Age-Related Macular Degeneration
The OMEGA Study: Use of Eye Drops to Treat Geographic Atrophy Associated With Age-Related Macular Degeneration (Dry AMD)
The purpose of this trial is to compare the ability of two doses of OT-551 ophthalmic solution and drug-free solution to safely and effectively treat geographic atrophy associated with age-related macular degeneration.
- Trial name
- OMEGA (NCT00485394)
- Testing
- OT-551
- Where
- 17 sites in United States
- Volunteers
- 198 people
- Sponsor
- Othera Pharmaceuticals
Dry Age-related Macular Degeneration, Geographic Atrophy
A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration
This study is designed to investigate the safety, PK/PD, biomarker and early clinical effects of repeat GEM103 IVT injections.
- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy, Macular Degeneration, Retinal Disease
- Trial name
- NCT04643886
- Testing
- GEM103
- Where
- 29 sites in United States
- Volunteers
- 62 people
- Sponsor
- Gemini Therapeutics, Inc.
Healthy
Chronic Cardiovascular and Gut-bacteria Effects of Phenolic Rich Oats in Adults With Above Average Blood Pressure
In this proposed human trial, the investigators aim to establish whether 4 weeks of daily consumption of beta-glucan matched meals providing either a high dose or a moderate dose of oat avenanthramides and phenolic acids leads to…
- Trial name
- NCT02847312
- Testing
- High avenanthramide, phenolic acid, Low avenanthramide, medium phenolic acid, Control
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Reading
Parkinson's Disease, Multiple System Atrophy
Individualized Transcranial Magnetic Stimulation in Parkinsonian Disorders
This clinical trial aims to evaluate whether individualized targeted repetitive transcranial magnetic stimulation (rTMS) can improve motor and non-motor symptoms in patients with parkinsonian disorders.
- Conditions
- Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
- Trial name
- NCT07570212
- Testing
- TMS
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University First Hospital
Dry Age-related Macular Degeneration, Macular Degeneration, Dry
Observation of the Natural Course of Age-related Macular Degeneration
This research will study natural course of dry AMD in Chinese population, screen fundus imaging indicators for patients with Chinese dry AMD, describe the clinical features of Chinese patients with dry AMD, and obtain a…
- Trial name
- NCT05418231
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Age-related Macular Degeneration
Global Atrophie Biomarker Evaluation Study (GABiE)
To investigate the use of microperimetry and SS-OCT in assessing the natural changes of retinal sensitivity and anatomy in the perilesional zone of geographic atrophy areas in patients with dry age-related macular degeneration.
- Trial name
- GABiE (NCT03935126)
- Testing
- Diagnostics
- Where
- 2 sites in United States, Switzerland
- Volunteers
- 3 people
- Sponsor
- Boehringer Ingelheim
Atrophy, Geographic
Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
The purpose of this study is to determine the safety and efficacy of GSK933776 in the treatment of geographic atrophy secondary to age-related macular degeneration.
- Trial name
- NCT01342926
- Testing
- GSK933776
- Where
- 41 sites in United States, Canada
- Volunteers
- 191 people
- Sponsor
- GlaxoSmithKline
Stargardt Disease, Macular Atrophy
Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease
This is a pharmacodynamics study of emixustat hydrochloride in subjects with macular atrophy secondary to Stargardt disease.
- Trial name
- NCT03033108
- Testing
- Emixustat
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Kubota Vision Inc.